Induction phase of general anesthesia
Conditions
Interventions
Fospropofol Group (F group):During the induction period, Group F received fospropofol 12 mg/kg.The MOAA/S score was assessed every 30 +/- 10 seconds after the initiation of fospropofol administration
Propofol Group (P group):During the induction period, Group P received propofol 2.0 mg/kg. The MOAA/S score was assessed every 30 +/- 10 seconds after the initiation of propofol administration until t
Fospropofol Combined with Propofol Group (FP group):During the induction period, Group FP first received fospropofol 6 mg/kg, followed by propofol 1.0 mg/kg after the completion of the fospropofol inj
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Female patients aged 18–65 years; 2. American Society of Anesthesiologists (ASA) physical status: I–III; 3. Body Mass Index (BMI): 18.5–30 kg/m^2; 4. Scheduled for elective gynecological laparoscopic surgery under general anesthesia with endotracheal intubation, with an expected surgery duration of 1.5–3 hours; 5. Willing to participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Individuals with contraindications to general anesthesia or those with a history of anesthesia-related complications; 2. Acute heart failure; unstable angina; myocardial infarction within 6 months prior to screening; moderate to severe valvular heart disease; resting ECG heart rate = 2.5 × ULN, TBIL >= 1.5 × ULN; 10. Abnormal kidney function: urea or blood urea nitrogen >=1.5 × ULN, serum creatinine above the upper limit of normal; 11. History of drug abuse, substance addiction, or alcoholism within 2 years prior to the screening period. Alcoholism is defined as an average daily alcohol intake exceeding 2 units (1 unit = 360 mL beer, or 45 mL of 40% distilled spirits, or 150 mL wine); 12. Patients who have not received standard antihypertensive treatment or have poorly controlled blood pressure (sitting systolic blood pressure during screening >= 160 mmHg or = 90 mmHg); 13. Patients with hypokalemia (serum potassium 4 L/day, urine osmolality < 200 mOsm/(kg·H2O), urine specific gravity < 1.005); 14. Patients allergic to or with contraindications for fospropofol, benzodiazepines, opioids, propofol, or flurbiprofen ester, and their components; 15. Participation in any clinical trial as a subject within the past 3 months; 16. Patients who, in the investigator's opinion, are unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Induction success rate;Time to successful induction;time to loss of eyelash reflex;the incidence and severity of injection pain;the incidence and severity of paresthesia; | — |
Secondary
| Measure | Time frame |
|---|---|
| time to awakening;time to discharge;rescue medication utilization;PONV score and management; | — |
Countries
China
Contacts
Public ContactJing Tian
Tianjin Medical University General Hospital
Outcome results
None listed